| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4004480 | American Journal of Ophthalmology | 2009 | 9 Pages |
Abstract
Intravitreal ranibizumab led to an increase in VA and regression of uveitis-associated CME in patients refractory to or intolerant of standard corticosteroid therapy. Further studies of this promising treatment are warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Nisha R. Acharya, Kevin C. Hong, Salena M. Lee,